GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » Cash-to-Debt

Accelerate Diagnostics (Accelerate Diagnostics) Cash-to-Debt : 0.39 (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Accelerate Diagnostics's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.39.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Accelerate Diagnostics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Accelerate Diagnostics's Cash-to-Debt or its related term are showing as below:

AXDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33   Med: 1.16   Max: 10186.46
Current: 0.39

During the past 13 years, Accelerate Diagnostics's highest Cash to Debt Ratio was 10186.46. The lowest was 0.33. And the median was 1.16.

AXDX's Cash-to-Debt is ranked worse than
76.62% of 864 companies
in the Medical Devices & Instruments industry
Industry Median: 1.845 vs AXDX: 0.39

Accelerate Diagnostics Cash-to-Debt Historical Data

The historical data trend for Accelerate Diagnostics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Accelerate Diagnostics Cash-to-Debt Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.81 0.46 0.57 0.59 0.34

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.84 0.58 0.34 0.39

Competitive Comparison of Accelerate Diagnostics's Cash-to-Debt

For the Medical Devices subindustry, Accelerate Diagnostics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Cash-to-Debt falls into.



Accelerate Diagnostics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Accelerate Diagnostics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Accelerate Diagnostics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accelerate Diagnostics  (NAS:AXDX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Accelerate Diagnostics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Executives
David Patience officer: Chief Financial Officer C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips director, officer: PRESIDENT AND CEO 11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz officer: Chief Technology Officer 3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie director 599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan director C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black director 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling officer: CFO 7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price officer: SVP & HEAD OF COM OPS AMERICAS 3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris director 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany director 1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller director C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm director C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts director 3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi director 870 WINTER STREET, WALTHAM MA 02451